BridgeMD
New treatment option for Coronary Disease
Official title Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG
ClinicalTrials.gov ID: NCT04779008
What this study is testing
- What it's testing
- Remote Ischemic preconditioning (RIPC) has been reported to improve myocardial microcirculation, promote collateral circulation recruitment, and improve myocardial perfusion in patients.Two large randomized controlled trials demonstrated a perioperative cardioprotective effect of RIPC (reduced troponin levels), but did not find that a single preoperative RIPC improved long-term outcomes of coronary artery bypass grafting(CABG).The effect of a single RIPC before CABG may be too short. This study aims to investigate whether long-term RIPC improved myocardial perfusion in patients 3 months and 6 months after CABG surgery , and to detect changes in blood vascular endothelial growth factor, Nitrc Oxide, adenosine，and Endothelin-1, and to observe MACCE event rates at 12 months.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Three coronary artery lesions, CABG surgery was planned
You likely can't join if
- The patients could not tolerate ripc;
- peripheral vascular disease affecting upper limbs
- Acute myocardial infarction complicated with cardiogenic shock，in recent 30 days,
- Emergency cases
- Severe structural heart disease and severe arrhythmia ；
- The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively;
See the full eligibility criteria
- Three coronary artery lesions, CABG surgery was planned
- The patients could not tolerate ripc;
- peripheral vascular disease affecting upper limbs
- Acute myocardial infarction complicated with cardiogenic shock，in recent 30 days,
- Emergency cases
- Severe structural heart disease and severe arrhythmia ；
- The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively;
- Severe liver, renal and pulmonary disease
- Mental disorder can't cooperate;
- Inability to give informed consent；
- Patients on glibenclamide or nicorandil, as these medications may interfere with RIC
- pregnant;
The study team makes the final eligibility decision.
Where it's taking place
- Zhengzhou, Henan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zhengzhou, Henan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.